Song Congkuan, Lu Zilong, Li Donghang, Pan Shize, Li Ning, Geng Qing
Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Front Oncol. 2022 Aug 10;12:890033. doi: 10.3389/fonc.2022.890033. eCollection 2022.
The surgical procedure for early-stage second primary non-small cell lung cancer (SP-NSCLC) remains controversial, especially for patients with previous lung cancer-directed surgery. This study aims to compare the survival after wedge resection and lobectomy for these patients.
Stage IA SP-NSCLC patients with clear clinical information were searched from the Surveillance, Epidemiology, and End Results (SEER) database. The Cox proportional hazard model, the competing risk model, and the Kaplan-Meier survival curve were used to describe the survival difference between wedge resection and lobectomy. A 1:1 propensity score matching (PSM) method was also performed to reduce the potential impact of confounding factors between the two groups.
Of the 320 eligible stage IA SP-NSCLC patients included in this study, 238 (74.4%) patients underwent wedge resection and 82 (25.6%) patients received lobectomy. The 5-year overall survival (OS) was 61.3% with wedge resection and was 66.1% with lobectomy. Both before and after PSM, wedge resection showed similar OS and lung cancer-specific mortality as lobectomy in the entire cohort. Additionally, in all subgroup analyses, wedge resection demonstrated equivalent survival to lobectomy. However, in the female, sublobectomy for the first primary lung cancer, and interval ≤ 24 months subgroups, wedge resection displayed a higher lung cancer-specific mortality than lobectomy (fine-gray test, all < 0.05).
Overall, wedge resection is comparable to lobectomy in OS for stage IA SP-NSCLC patients with previous lung cancer-directed surgery. Therefore, we believe that wedge resection may be sufficient for these patients, although, in some cases, wedge resection has a higher lung cancer-specific mortality rate than lobectomy.
早期第二原发性非小细胞肺癌(SP-NSCLC)的手术方式仍存在争议,尤其是对于既往接受过肺癌针对性手术的患者。本研究旨在比较这些患者楔形切除术和肺叶切除术术后的生存率。
从监测、流行病学和最终结果(SEER)数据库中搜索具有明确临床信息的IA期SP-NSCLC患者。采用Cox比例风险模型、竞争风险模型和Kaplan-Meier生存曲线来描述楔形切除术和肺叶切除术之间的生存差异。还采用1:1倾向评分匹配(PSM)方法来减少两组之间混杂因素的潜在影响。
本研究纳入的320例符合条件的IA期SP-NSCLC患者中,238例(74.4%)患者接受了楔形切除术,82例(25.6%)患者接受了肺叶切除术。楔形切除术的5年总生存率(OS)为61.3%,肺叶切除术为66.1%。在PSM前后,整个队列中楔形切除术的OS和肺癌特异性死亡率与肺叶切除术相似。此外,在所有亚组分析中,楔形切除术的生存率与肺叶切除术相当。然而,在女性、首次原发性肺癌为亚肺叶切除以及间隔≤24个月的亚组中,楔形切除术的肺癌特异性死亡率高于肺叶切除术(精细灰色检验,均<0.05)。
总体而言,对于既往接受过肺癌针对性手术的IA期SP-NSCLC患者,楔形切除术在OS方面与肺叶切除术相当。因此,我们认为楔形切除术可能对这些患者足够,尽管在某些情况下,楔形切除术的肺癌特异性死亡率高于肺叶切除术。